Inventor · disambiguated record
Sean P. Brown
Also filed as: BROWN SEAN · BROWN SEAN P · BROWN SEAN POMEROY
27 granted patents·5 pending applications·282 citations·filing 1999–2023
96Inventor score
Top patents by PatentIndex Score
32 records- 0197US10300075B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2018·Granted May 28, 2019·22 cites·39 claims
- 0297US9562061B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2015·Granted Feb 7, 2017·39 cites·30 claims
- 0396US11629136B1Substituted pyridine derivatives as SARM1 inhibitorsNURA BIO INC·Filed 2022·Granted Apr 18, 2023·4 cites·29 claims
- 0494US7582803B2Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disordersAMGEN INC·Filed 2006·Granted Sep 1, 2009·17 cites·19 claims
- 0593US11970481B1Substituted pyridine derivatives as SARM1 inhibitorsNURA BIO INC·Filed 2023·Granted Apr 30, 2024·4 cites·18 claims
- 0693US10632128B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2019·Granted Apr 28, 2020·5 cites·49 claims
- 0793US7037918B2Inhibitors of glycogen synthase kinase 3CHIRON CORP·Filed 2002·Granted May 2, 2006·49 cites·3 claims
- 0892US12110285B2Substituted pyridine derivatives as SARM1 inhibitorsNURA BIO INC·Filed 2023·Granted Oct 8, 2024·1 cites·19 claims
- 0991US10500213B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2019·Granted Dec 10, 2019·6 cites·46 claims
- 1091US10100063B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2016·Granted Oct 16, 2018·8 cites·12 claims
- 1190US11945796B2Substituted pyridine derivatives as SARM1 inhibitorsNURA BIO INC·Filed 2021·Granted Apr 2, 2024·2 cites·66 claims
- 1290US6489344B1Inhibitors of glycogen synthase kinase 3CHIRON CORP·Filed 1999·Granted Dec 3, 2002·76 cites·34 claims
- 1386US10494381B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2018·Granted Dec 3, 2019·3 cites·13 claims
- 1486US8030354B2Substituted biphenyl GPR40 modulatorsAMGEN INC·Filed 2008·Granted Oct 4, 2011·11 cites·96 claims
- 1583US8450522B2Conformationally constrained carboxylic acid derivatives useful for treating metabolic disordersBROWN SEAN P·Filed 2009·Granted May 28, 2013·9 cites·17 claims
- 1683US7687526B2Benzo-fused compounds for use in treating metabolic disordersAMGEN INC·Filed 2007·Granted Mar 30, 2010·5 cites·18 claims
- 1781US11306107B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2017·Granted Apr 19, 2022·2 cites·11 claims
- 1881US7572934B2Substituted biphenyl GPR40 modulatorsAMGEN INC·Filed 2008·Granted Aug 11, 2009·5 cites·70 claims
- 1974US10836779B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2018·Granted Nov 17, 2020·0 cites·8 claims
- 2073US8748462B2Spirocyclic GPR40 modulatorsBROWN SEAN P·Filed 2009·Granted Jun 10, 2014·2 cites·25 claims
- 2172US11224601B1Compounds that inhibits MCL-1 proteinAMGEN INC·Filed 2020·Granted Jan 18, 2022·0 cites·15 claims
- 2269US10821115B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2020·Granted Nov 3, 2020·0 cites·43 claims
- 2369US7195879B2Method for identifying modulators of NAv ion channelsORTHO MCNEIL PHARM INC·Filed 2002·Granted Mar 27, 2007·12 cites·3 claims
- 2464US2009275598A1Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disordersAMGEN INC·Filed 2009·Application pending·0 cites
- 2563US12404265B2Substituted pyridine derivatives as SARM1 inhibitorsNURA BIO INC·Filed 2021·Granted Sep 2, 2025·0 cites·16 claims
- 2653US2023312606A1Mcl-1 inhibitor formulationsAMGEN INC·Filed 2021·Application pending·0 cites
- 2749US11364248B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2018·Granted Jun 21, 2022·0 cites·45 claims
- 2848US11279712B2Macrocyclic compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2018·Granted Mar 22, 2022·0 cites·21 claims
- 2944US11274105B2Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonistsAMGEN INC·Filed 2019·Granted Mar 15, 2022·0 cites·15 claims
- 3043US2003022813A1Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channelsFiled 2002·Application pending·0 cites
- 3143US2010137323A1Benzo-fused compounds for use in treating metabolic disordersAMGEN INC·Filed 2010·Application pending·0 cites
- 3240US2023117777A1Methylation of mcl-1 compoundsAMGEN INC·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →